• 1
    Baker SD, Mc Clatchey KD. Carcinoma of the nasopharynx in childhood. Otolarynol. 1981; 89: 555559.
  • 2
    Liebowitz D, Kieff E. Epstein–Barr virus. In: RoizmanB, WhitleyRJ, LopezC, editors. The human herpes virus. New York: Raven, 1993: 107172.
  • 3
    Berberoglu S, Ilhan F, Cetindag S, Sunter O. Nasopharyngeal carcinoma in Turkish children: review of 33 cases. Pediatr Hematol Oncol. 2001; 18: 309315.
  • 4
    Lombardi F, Gasparini M, Gianni C, et al. Nasopharyngeal carcinoma in childhood. Med Pediatr Oncol. 1993; 10: 243250.
  • 5
    Mertens R, Granzen B, Lassay L, et al. Nasopharyngeal carcinoma in childhood and adolescence. Cancer. 1997; 80: 951959.
  • 6
    Krueger GRF, Wustrow J. Current classification of nasopharyngeal carcinoma at Cologne University. In: GrundmannE, KruegerGRF, AblashiDV, editors. Nasopharyngeal carcinoma. vol. 5. Stuttgart: Verlag, 1981: 1115.
  • 7
    Lee AWM, Foo W, Poon YF, et al. Staging of nasopharyngeal carcinoma: evaluation of N-staging by Ho and UICC/AJCC systems. Union Internationale Contre le Cancer. American Joint Committee for Cancer. Clin Oncol. 1996; 8: 160166.
  • 8
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 9
    Blutters-Sawatzki R, Grathwohl J, Mertens R, Lampert F. Severe cardiotoxicity of high-dose 5-fluorouracil in combination with folinic acid, cisplatin and methotrexate in a 14-year-old boy with nasopharyngeal carcinoma (Schmincke tumor). Oncology. 1995; 52: 291294.
  • 10
    Serin M, Erkal HS, Elhan AH, et al. Nasopharyngeal carcinoma in childhood and adolescence. Med Pediatr Oncol. 1998; 31: 498505.
  • 11
    Uzel O, Ozger S, Sahinler I, Turkan E, et al. Nasopharyngeal carcinoma in childhood: long-term results of 32 patients. Radiother Oncol. 2001; 58: 137141.
  • 12
    Wolden S, Steiherz P, Kraus DH, et al. Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer. Int. J Rad Oncol. 2000; 48: 859864.
  • 13
    Zubizarreta P, D'Antonio G, Raslawski E, et al. Nasopharyngeal carcinoma in childhood and adolescence: a single-institution experience with combined therapy. Cancer. 2000; 89: 690695.
  • 14
    Ayan I, Altun M. Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol Phys. 1996; 35: 485492.
  • 15
    Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys. 1995; 32: 859877.
  • 16
    Bornkamm GW. Virologisch-serologische Diagnostik des Nasopharynxkarzinoms. In: BornkampGW, WannemacherM, editors. Nasopharynx-tumoren. Munich: Urban & Schwarzenberg, 1984: 1521.
  • 17
    Niedobitek G, Young LS. Epstein–Barr virus persistence and virus-associated tumors. Lancet. 1994; 343: 333335.
  • 18
    Arush MW, Stein ME, Rosenblatt E, et al. Advanced nasopharyngeal carcinoma in the young: The Northern Israel Oncology Center experience, 1973–1991. Pediatr Hematol Oncol. 1995; 12: 271306.
  • 19
    Al-Sarraf M, LeBlanc M, Giri PGS, et al. Superiority of chemo-radiotherapy (CT-RT) versus radiotherapy (RT) in patients (PTS) with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG8892), RTOG 8817, ECOG 2388) randomized study. [abstract no. 882]. Proceedings of the American Society of Clinical Oncology. 1996;15: 313.
  • 20
    Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23: 261270.
  • 21
    Frommhold H, Gauwerk F. Zur Strahlenbehandlung der Epipharynxtumoren. Strahlentherapie. 1972; 144: 509514.
  • 22
    Barjaktarevic ZD, Golubicic V. Undifferentiated nasopharyngeal carcinoma in children: a report of four cases. J Chemother. 1995; 7: 249252.
  • 23
    Pao WJ, Hustu HO, Douglass EC, et al. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989; 17: 299305.
  • 24
    Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III Randomized Intergroup Study 0099. J Clin Oncol. 1998; 16: 13101317.
  • 25
    Douglass EC, Fontanesi J, Ribeiro RC, Hawkins E. Improved long-term disease-free survival in nasopharyngeal carcinoma (NPC) in childhood and adolescence: a multi-institution treatment protocol. [abstract no. 1470]. Proceedings of the American Society of Clinical Oncology. 1996;15: 46.
  • 26
    Mertens R, Lassay L, Heimann G. [Combined treatment of nasopharyngeal cancer in children and adolescents—concept of a study.] Klin Padiatr. 1993; 205: 241248.
  • 27
    Ahern V, Jenkin D, Banerjee D, et al. Nasopharyngeal carcinoma in the young. Clin Oncol. 1994; l 6: 2430.
  • 28
    Mertens R, Karstens JH, Ammon J, et al. Bisherige Erfahrungen der Interferontherapie an 7 Patienten mit NPC. In: WannenmacherM, editor. Nasopharynxtumoren. Munich: Urban & Schwarzenberg, 1984: 188193.
  • 29
    Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 1993; 120: 115118.
  • 30
    De-En H, Ling XS, Hu J, et al. The effects of radiotherapy on the immune system of patients with nasopharyngeal carcinoma. Brit J Radiol. 1988; 61: 305308.
  • 31
    Tamura S, Yamazaki A, Kunimoto M, et al. [Impaired long-term T cell immunity to Epstein–Barr virus in patients with nasopharyngeal carcinoma.] Jpn J Cancer Res. 1992; 83: 445449.
  • 32
    Tan GL. [A study of T-lymphocyte subsets, IL-2 production and IL-2 receptor expression in peripheral blood lymphocytes in patients with nasopharyngeal carcinoma.] Chung Hua Erh Pi Yen Hou Ko Tsa Chih. 1993; 28: 167169.
  • 33
    Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumor necrosis factor and their regulation by interferon. Nature. 1985; 318: 665668.
  • 34
    Fleischmann R, Fleischmann M. Mechanisms of interferons, antitumor agents. In: FleischmannR, FleischmannM, BaronS, et al., editors. Interferon—principles and medical applications. Galveston: University of Texas Medical Branch at Galveston, 1992: 299308.
  • 35
    Guang-Wu H, Sunagawa M, Jien-En L, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope. 2000; 110: 20662069.
  • 36
    Wakisaka N, Wen QH, Yoshizaki T, et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope. 2000; 109: 810814.
  • 37
    Yoshizaki T, Horikawa T, Qing-Chun R, et al. Induction of interleukin-8 by Epstein–Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 2001; 7: 19461951.
  • 38
    Li J, Huang G, Nong H, et al. [Expression of vascular endothelial growth factor and tumor angiogenesis correlates with biological behaviours of nasopharyngeal carcinoma.] Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1999; 13: 343344.
  • 39
    Qian CN, Min HQ, Lin HL, et al. Combination of angiogenesis inhibitor TNP-470 with cytotoxic drugs in experimental therapy of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2000; 109: 641645.
  • 40
    Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987; 47: 544551.
  • 41
    Fidler F. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst. 2001; 93: 10401042.